Additionally, in patients with EGFR wild type, it was reported that Erlotinib has similar clinical efficacy compared to chemotherapy in patients with pre-treated advanced NSCLC (wild-EGFR) and no known molecular targetable alterations [12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.